Menveo

Meningococcal Group Y Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm197 Protein, N. M, the active ingredient in Menveo, is a vaccine presented as an injectable solution for intramuscular use. It induces immunity against invasive disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y in individuals at risk, including adolescents, travelers and those in high‑density living settings.

GNH USA supplies Menveo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Menveo is a conjugate vaccine that targets meningococcal polysaccharide antigens to prevent invasive meningococcal disease. - Individuals aged 2 months to 55 years: induces protective antibodies against serogroups A, C, W‑135 and Y. - Travelers to endemic regions: reduces the risk of meningococcal infection during travel. - College students living in dormitories: provides protection in high‑density residential settings.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient elevation of body temperature. - Headache: mild to moderate headache after vaccination. - Fatigue: temporary feeling of tiredness. - Myalgia: muscle aches in the days following injection.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurologic disorder reported post‑vaccination. - Seizures: infrequent occurrence, especially in febrile children. - Severe hypotension: marked drop in blood pressure after injection. - Extensive local reaction: large area of induration or necrosis at the site.

Before administering Menveo, consider the following precautions: - Allergy assessment: avoid in individuals with severe hypersensitivity to any vaccine component. - Pregnancy: use only if clearly needed; data on safety are limited. - Immunocompromised patients: vaccine may be less effective; assess timing relative to immunosuppressive therapy. - Concurrent vaccines: may be given with other vaccines at separate sites. - Age restriction: not approved for persons older than 55 years. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines can interact with other agents that affect immune response. Major Interactions (Avoid): - Live bacterial vaccines: do not administer simultaneously; separate by at least 4 weeks. - Severe allergic reaction to a previous dose: contraindicates further dosing. Moderate Interactions (Monitor Closely): - Immunoglobulin therapy: may reduce vaccine efficacy; avoid within 2 weeks before or after vaccination. - Blood products: can interfere with immune response if given close to vaccination. - Antipyretics: may mask fever, a common post‑vaccination sign; use as needed after monitoring.